# EDGAR Filing Document

**Accession Number:** 0001402328
**File Stem:** 0001683168-23-001754
**Filing Date:** 2023-3
**Character Count:** 6780
**Document Hash:** 76756f012bb09f2b4417a9e63467fdff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-23-001754.hdr.sgml**: 20230324

**ACCESSION NUMBER**: 0001683168-23-001754

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230324

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**FILED AS OF DATE**: 20230324

**DATE AS OF CHANGE**: 20230324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sunshine Biopharma, Inc
- **CENTRAL INDEX KEY:** 0001402328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 205566275
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41282
- **FILM NUMBER:** 23760466

**BUSINESS ADDRESS:**
- **STREET 1:** 6500 TRANS-CANADA HIGHWAY
- **STREET 2:** 4TH FLOOR
- **CITY:** POINTE-CLAIRE
- **STATE:** A8
- **ZIP:** H9R 0A5
- **BUSINESS PHONE:** 514-426-6161

**MAIL ADDRESS:**
- **STREET 1:** 6500 TRANS-CANADA HIGHWAY
- **STREET 2:** 4TH FLOOR
- **CITY:** POINTE-CLAIRE
- **STATE:** A8
- **ZIP:** H9R 0A5

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mountain West Business Solutions, Inc
- **DATE OF NAME CHANGE:** 20071030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** mountain west business solutions,inc
- **DATE OF NAME CHANGE:** 20070607

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**Form 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **<u>March 24, 2023</u>**

**<u>SUNSHINE BIOPHARMA, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Colorado</u>** | **<u>001-41282</u>** | **<u>20-5566275</u>** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer ID No.) |

---

**6500 Trans-Canada Highway**

**4th Floor**

**<u>Pointe-Claire, Quebec, Canada H9R0A5</u>**

(Address of principal executive offices) (zip code)

**<u>(514) 426-6161</u>**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
| Common Stock, par value $0.001 | SBFM | The Nasdaq Stock Market LLC |
| Common Stock Purchase Warrants | SBFMW | The Nasdaq Stock Market LLC |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On March 24, 2023, Sunshine Biopharma, Inc. (the "Company") received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, because the closing bid price for the Company's common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the "Minimum Bid Price Requirement").

The notification has no immediate effect on the listing of the Company's common stock. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from March 24, 2023, or until September 20, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before September 20, 2023, the bid price of the Company's common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement.

The notification letter also disclosed that in the event the Company does not regain compliance with the Minimum Bid Price Requirement by September 20, 2023, the Company may be eligible for additional time. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. However, if it appears to the staff of Nasdaq (the "Staff") that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that its securities will be subject to delisting.

The Company intends to continue actively monitoring the bid price for its common stock between now and September 20, 2023 and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Dated: March 24, 2023 | **SUNSHINE BIOPHARMA, INC.** |
|  | (Registrant) |
|  | By: <u>/s/ Dr. Steve N. Slilaty&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Dr. Steve N. Slilaty, Chief Executive Officer |

---